SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (IC90 = 0.88 nM) 27.5-fold more potent than remdesivir against SARS-CoV-2 in vitro, with limited toxicity in cell culture. Through the use of a drug resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A. We demonstrate the in vivo efficacy of plitidepsin treatment in two mouse models of SARS-CoV-2 infection with a reduction of viral replication in the lungs by two orders of magnitude using prophylactic treatment. Our results indicate that plitidepsin is a promising therapeutic candidate for COVID-19.
Over the last 20 years, three novel coronaviruses (CoV) have been introduced into the human population causing significant morbidity and mortality. The Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) epidemics were each limited in scope, but both are associated with severe disease and high mortality rates (1–3). The ongoing COVID-19 pandemic caused by the SARS-CoV-2 virus, is the result of a zoonotic transmission event, similar to previous coronavirus epidemics (4–7). Recent studies have detected many SARS-like and MERS-like coronaviruses in natural bat reservoirs and shown them to be capable of replication in human lung cells in vitro (8–10). This suggests the presence of a large reservoir of coronaviruses with pandemic potential. Antiviral therapeutics are urgently needed to combat SARS-CoV-2 in the current pandemic and will be the first line of defense for the future coronavirus epidemics that appear more likely as the human population expands in close contact with animal reservoirs.
COVID-19 is a viral-induced inflammatory disease of the airways and lungs with multi-organ involvement that can cause severe respiratory and systemic issues. SARS-CoV-2 replication in the lungs leads to inflammatory, innate and adaptive immune responses that cause significant host tissue damage (3, 11). COVID-19 can lead to end-stage lung disease and systemic involvement that currently has limited treatment options and poor prognoses. The current standards of care include oxygen therapy and ventilation, along with the antiviral remdesivir and the anti-inflammatory dexamethasone. Remdesivir (12, 13) and dexamethasone (14) have each improved patient outcomes in clinical trials and have been approved for emergency use by regulatory agencies, but remdesivir in particular has shown limited efficacy (15) and dexamethasone is a steroid that does not directly inhibit viral replication. This leaves a continued need for the development or repurposing of antiviral drugs for the treatment of COVID-19.
Our previously published SARS-CoV-2 (16) and pan-coronaviral (17) interactomes highlighted 332 host proteins that are likely to play a role in the viral life cycle of SARS-CoV-2. In that work we tested 47 existing drugs that were known to modulate these identified host proteins, with many of these drugs showing significant antiviral activity against SARS-CoV-2 in cell culture (16). Of the inhibitors tested, those that targeted the eukaryotic translation machinery (eIF4H interacts with SARS-CoV-2 Nsp9) demonstrated particularly potent antiviral activities. Zotatafin (18), an inhibitor of eIF4A (a partner of eIF4H), had a 90% inhibitory concentration (IC90) of 154 nM and ternatin-4 (19), an inhibitor of eEF1A which has potential interactions with multiple coronavirus proteins (17), had an IC90 of 15 nM against SARS-CoV-2 in Vero E6 cells (16).
In an effort to further explore the therapeutic potential of host eEF1A as a target for the treatment of COVID-19, we evaluated the eEF1A inhibitor plitidepsin (aplidin), which has limited clinical approval for the treatment of multiple myeloma. Plitidepsin has also successfully completed a phase I/II clinical study for the treatment of COVID-19 (20, 21) by the pharmaceutical company PharmaMar and is moving forward into a Phase II/III COVID-19 study. We first tested plitidepsin inhibition of SARS-CoV-2 replication using an immunofluorescence-based antiviral screening assay in Vero E6 cells (22). Plitidepsin inhibited SARS-CoV-2 with an IC90 of 1.76 nM (Fig. 1B), which was 9-fold more potent than ternatin-4 and 87.5-fold more potent than zotatafin in the same assay (16). We next tested plitidepsin in the same antiviral assay using a human cell line (hACE2-293T). The anti-SARS-CoV-2 activity of plitidepsin was even more potent in human cells, with an IC90 of 0.88 nM (Fig. 1D), which is 27.5-fold more potent then remdesivir tested in the same cell line (Fig. 1C). The cytotoxicity of plitidepsin was examined in parallel with antiviral activity; at all concentrations, in both cell types, we observed a cytostatic impact on cell proliferation (Fig. 1, B and D). We have previously found the lack of a dose response curve in our cytotoxic assay to be suggestive of a cytostatic, rather than cytotoxic, effect on cells, but further work is required to confirm this hypothesis. Finally we tested the antiviral effect of plitidepsin in an established model of human pneumocyte-like cells (23, 24). We found that treatment with plitidepsin inhibited SARS-CoV-2 replication (Fig. 1E) with an IC90 of 3.14 nM and a selectivity index of 40.4, suggesting that plitidepsin has potent antiviral activity in primary human lung cells.
In an effort to better understand the mechanism of action through which plitidepsin inhibits SARS-CoV-2 infection, we performed a time-of-addition assay in which plitidepsin or remdesivir was added to hACE2-293T cells at -2, 0, +2, or +4 hours relative to infection. In this 8 hour single-cycle infection, we found that 20 nM plitidepsin strongly inhibited NP-expression even when added 4 hours after infection (Fig. 1F). This is indicative of a cytoplasmic replication stage inhibitor, which is consistent with the predicted antiviral mechanism of a known translation inhibitor.
Remdesivir is part of the current standard of care for the treatment of COVID-19 (25, 26). We therefore assessed the dynamics between the antiviral effects of plitidepsin and remdesivir when used together in vitro. Our analysis using the Synergyfinder (27) software suggests that plitidepsin has an additive effect with remdesivir (fig. S2) and would be a potential candidate to be considered in a combined therapy by having an additive effect with the current standard of care.
Plitidepsin inhibits the activity of the host factor eEF1A and is predicted to interact with the same binding site as didemnin B, which is structurally related to plitidepsin, and the structurally unrelated ternatin-4. Exogenous overexpression of a A399V mutant of eEF1A confers resistance in cancer cells to both didemnin B (28) and ternatin-4 (29) inhibition and we predicted that it may similarly impact plitidepsin. We examined whether this A399V mutation could mitigate the observed anti-SARS-CoV-2 activity of plitidepsin. First, we transiently co-transfected 293T cells with expression plasmids for hACE2 and either eEF1A-WT or eEF1A-A399V, which were confirmed to be expressed in approximately 30% of cells via immunofluorescent staining for the Flag epitope (fig. S1). We then measured the antiviral activity of plitidepsin against SARS-CoV-2 in these transfected 293T cells. Transfection with eEF1A-A399V, but not eEF1A-WT, increased the IC90 of plitidepsin by greater than 10-fold (Fig. 2A). Interestingly, no impact from the A399V mutant transfection was observed on plitidepsin inhibition of cell proliferation (Fig. 2D), consistent with observations of ternatin-4 (29). The differential effect of eEF1A-A399V transient transfection between the antiviral and anti-proliferative impact of plitidepsin is consistent with previous findings that coronaviruses are significantly more sensitive to translation perturbations than the host cell (30, 31). We then generated an eEF1A-A399V CRISPR knock-in 293T cell line (293T-A399V) to further evaluate the role of eEF1A inhibition in the antiviral activity of plitidepsin. We found that this 293T-A399V cell line was refractory (greater than 12-fold) to the SARS-CoV-2 antiviral activity of plitidepsin as compared to the parental cell line (Fig. 2B), while not similarly impacting remdesivir inhibition (Fig. 2C). Furthermore, we found that plitidepsin antiviral activity could be almost fully restored through transient transfection of the 293T-A399V cells with wild type, but not mutant, eEF1A (Fig. 2B). This 293T-A399V cell line was also resistant to the anti-proliferative activity of plitidepsin and this could only be partially rescued by transfection of the wild type protein (Fig. 2E), again similar to previous results with ternatin-4 (29). Furthermore siRNA silencing of eEF1A protein expression during SARS-CoV-2 infection lead to a large reduction in viral N protein levels while not similarly impacting the GAPDH control (Fig. 2F). Taken together, this evidence indicates that the antiviral activity of plitidepsin is mediated through eEF1A inhibition and confirms eEF1A as a druggable target for the inhibition of SARS-CoV-2 replication.
We next explored the impact of plitidepsin treatment on viral RNA and protein production over the course of SARS-CoV-2 infection. We analyzed the SARS-CoV-2 genomic and N sub-genomic RNA content of Vero E6 cells infected with SARS-CoV-2 at an MOI of 1 at 4, 8, 12, and 24 hours post infection in the presence or absence of equivalent inhibitory doses of plitidepsin or remdesivir. We found that plitidepsin significantly reduced genomic RNA content at 8 and 12 hours post infection and fell just short of significance at the 24 hour time point, similar to remdesivir treatment (Fig. 3A). Interestingly, plitidepsin had a much greater impact on the accumulation of the N sub-genomic RNA. Plitidepsin greatly reduced the sub-genomic RNA expression as early as 4 hours post infection and maintained a significant impact throughout the time course (Fig. 3B). Remdesivir had no effect on N sub-genomic RNA at 4 hours, but did show a reduction at all other time points tested. We then measured the viral N protein levels in the presence and absence of plitidepsin or remdesivir treatment. Similar to RNA levels, plitidepsin had a more potent and sustained inhibition of the expression the N protein over the time course of infection compared to remdesivir (Fig. 3, C and D). This specific inhibition of N sub-genomic RNA expression, particularly early in infection, is likely a result of the inhibition of viral translation by plitidepsin. It has been shown previously that coronaviruses are highly sensitive to translation inhibitors (30, 31) and that negative sense genome accumulation is more greatly impacted than the positive sense (32). The current model of coronavirus discontinuous transcription (33) has been guided by evidence that sub-genomic RNA formation occurs during negative strand synthesis (34). Therefore a translation inhibitor that more greatly impacts negative sense RNA production would also be expected to specifically reduce sub-genomic RNA formation and accumulation, as we observe with plitidepsin. Furthermore, consistent with an impact of plitidepsin in protein translation, N protein levels were more greatly reduced in plitidepsin treated cells compared to remdesivir at 24 hours post infection, when levels of N RNA were equivalent between these two treatments.
Plitidepsin has been clinically developed for the treatment of multiple myeloma with a well-established safety profile and pharmacokinetics (35–38). Initially, plitidepsin underwent a large clinical development program in which, cancer patients were treated with plitidepsin as a single agent in several phase I and II clinical trials. Results gathered from these clinical studies demonstrated that the probability of having cardiac adverse events, a concern in COVID-19 patients, was not significantly impacted by plitidepsin treatment (39–41), although these events were found in other chemically related compounds which display a different mechanism of action (42, 43). It is worth highlighting that plitidepsin had a good safety profile in a Phase I clinical trial (44), which administered a total of 11.4 mg spaced over 5 days of treatment. The dose level used in the COVID-19 proof of concept phase I study (21) had a maximum total of 7.5 mg spaced over 3 days.
Based on this clinical safety data and good pharmacokinetics (fig. S3A) we determined that a concentration of plitidepsin an order of magnitude greater than the demonstrated in vitro IC90 could be safely achieved in the lungs of mice using a single daily dose. Therefore, we tested the in vivo efficacy of plitidepsin in two different established animal models of SARS-CoV-2 infection. First we used a human ACE2 expressing adenovirus to transduce the naturally resistant wild type BALB/c mice and sensitize them to SARS-CoV-2 infection (Fig. 4A) (45). Five days post adenovirus transduction, mice were infected with 1 × 104 pfu of SARS-CoV-2. As a proof-of-principle experiment, we performed prophylactic dosing with 0.3 mg/kg or 1 mg/kg plitidepsin 2 hours prior to infection with SARS-CoV-2. The 0.3 mg/kg group received continued dosing once per day for 2 more days, while the 1 mg/kg group received only that single dose (Fig. 4B). SARS-CoV-2 lung titers were quantified from two independent experiments for the plitidepsin groups and compared to vehicle and remdesivir controls (Fig. 4C). There was nearly a 2 log reduction in SARS-CoV-2 viral titers in the lungs of the 0.3 mg/kg plitidepsin group compared to the vehicle control group, while there was a 1.5 log reduction observed from the single dose of 1 mg/kg plitidepsin. It should be noted that we used a very high concentration of remdesivir in these assays (50mg/kg) because of the known high concentration of esterases present in mouse serum that degrade remdesivir (46).
We then performed a study in the K18-hACE2 mouse model (Fig. 5A), which supports a robust SARS-CoV-2 infection (45, 47), in which the 0.3 mg/kg dosage of plitidepsin was assessed for ability to reduce viral titers and inflammation in the lung. K18-hACE2 mice were treated with one daily dose of plitidepsin for 3 days starting 2 hours before infection with SARS-CoV-2 (Fig. 5B). We found a 2 log reduction in viral lung titers at day 3, similar to two daily 50 mg/kg doses of remdesivir (Fig. 5C). Histopathology analysis (Fig. 5D) also showed a reduction a lung inflammation in plitidepsin treated mice (histopathology score of 1/16) over vehicle treated (histopathology score of 5.4/16) and remdesivir treated (histopathology score of 2.3/16) mice at day 3 post infection (Fig. 5E). There was no peribronchiolar inflammation noted in the plitidepsin treated group. Taken together these experiments show that plitidepsin treatment can reduce the replication of SARS-CoV-2 by 2 orders of magnitude and reduce lung inflammation in vivo and has significant potential for clinical efficacy for the treatment of COVID-19.
The ongoing SARS-CoV-2 pandemic has created the immediate need for antiviral therapeutics that can be moved into the clinic within months rather than years. This led us to screen clinically-approved drugs with established bioavailability, pharmacokinetics and safety profiles. Our previous study of the SARS-CoV-2 interactome (16) led us to eEF1A as a druggable target with the potential for potent inhibition of SARS-CoV-2 in vitro. eEF1A has been previously described to be an important host factor for the replication of many viral pathogens (48–50), including influenza virus (51) and RSV (52). Specifically, it has been found to be involved in transmissible gastroenteritis coronavirus (TGEV) replication (53) and was detected in SARS-CoV virions (54). Therefore, inhibition of eEF1A as a strategy for the treatment of viral infection may extend to other human coronaviruses and beyond to unrelated viral pathogens. This potential for broad-spectrum antiviral activity makes plitidepsin an intriguing candidate for further exploration as a treatment for viral infections with no clinically approved therapeutics. It is also important to note that a host-targeted antiviral such as plitidepsin offers protection from naturally occurring viral mutants, such as the variant recently discovered in the United Kingdom (55, 56), to which viral-targeted therapeutics and vaccines are more susceptible.
In our animal experiments, we did detect a slight body weight loss of mice that were treated with plitidepsin daily, while mice that received a single 1 mg/kg dose did not lose any weight while still exhibiting reductions in viral lung titers (fig. S3B). It is unclear whether this observed toxicity is mouse-specific and while toxicity is a concern with any host-targeted antiviral, the safety profile of plitidepsin is well established in humans. Furthermore, the dose of plitidepsin being used in an ongoing COVID-19 clinical trial is significantly less than used in these experiments and it has been well tolerated in patients with minimal side effects. Interestingly, the most well established and effective steroid for the treatment of COVID-19, dexamethasone (14), is also a commonly used treatment for multiple myeloma (57). This has led to plitidepsin already having an established safety profile with concurrent dexamethasone treatment (58, 59) and should allow for clinicians to treat with both drugs if warranted. This study establishes plitidepsin as a host-targeted anti-SARS-CoV-2 agent with in vivo efficacy. We believe that our data and the initial positive results from PharmaMar’s clinical trial suggests that plitidepsin should be strongly considered for expanded clinical trials for the treatment of COVID-19.
Funding: This research was partly funded by the Defense Advanced Research Projects Agency (HR0011-19-2-0020) to A.G-S., N.J.K., and K.M.S.; by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C); by supplements to NIAID grant U19AI135972 and DoD grant W81XWH-20-1-0270; by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by anonymous donors to A.G-S. This research was also funded by the Huffington Foundation to T.Z..; by the National Institutes of Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, P01A1063302, and R01AI122747 to N.J.K.; 1R01CA221969 and 1R01CA244550 to K.M.S.; and F32CA239333 to M.B.); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between UCSF, UCB, and GSK (grant number 133122P to N.J.K.); by the Laboratoire d’Excellence ‘‘Integrative Biology of Emerging Infectious Diseases’’ grant ANR-10-LABX-62-IBEID (to M.V.); and by funding from FastGrants COVID19 grant from the Emergent Ventures program at the Mercatus Center of George Mason University, F. Hoffmann-La Roche, Vir Biotechnology, the Roddenberry Foundation, and gifts from QCRG philanthropic donors to N.J.K.. S.Y. received funding from Swiss National Foundation (SNF) Early Postdoc.Mobility fellowship (P2GEP3_184202).
Author contributions: K.M.W., N.J.K, and A.G.S. conceived and co-directed the study; K.M.W., N.J.K., A.G.S., R.Ros., S.Y., L.C., M.B., P.A., T.Z., and K.M.S. designed the experiments; K.M.W, R.Ros, S.Y., T.K, L.M., E.M., S.J., J.B., A.R., and M.D. performed
in vitro experiments; K.M.W, R.Ros, S.Y., M.B.U,, R.Rath., C.M.R., M.J.G., A.L., P.A., and M.S. performed
in vivo experiments; K.M.W, N.J.K, A.G.S, R.Ros., S.Y., M.B., J.M.F., K.O., M.J.G., A.L., P.A., M.V., and K.M.S. interpreted the data; and K.M.W, N.J.K, A.G.S, R.Ros., S.Y., S.J., M.B., M.D., P.A., and T.Z. wrote the manuscript. All authors read and accepted the manuscript.
Competing interests: The García-Sastre Laboratory has received research support from Pfizer, Senhwa Biosciences and 7Hills Pharma. Adolfo García-Sastre has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Accurius and Esperovax. The Krogan Laboratory receives funding from Roche and VIR and Nevan Krogan has consulting agreements with Maze Therapeutics and Interline Therapeutics. Kevan Shokat has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Revolution Medicines, Type6 Therapeutics, Venthera, Wellspring Biosciences (Araxes Pharma), Turning Point Therapeutics, Ikena, Nextech. María José Guillén, Alejandro Losada, and Pablo Avilés are employees and shareholders of PharmaMar, SA (Madrid, Spain).
Data and materials availability: Plitidepsin is available from PharmaMar for non-commercial use under an MTA. All relevant data are included within this manuscript and all materials other than plitidepsin are readily available upon request from Kris White, Nevan Krogan, or Adolfo Garcia-Sastre. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit
https://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.